In conclusion, we identified E2F1 and E2F6 as new important indicators that can be used in combination with commonly used clinical indicators to assess the risk of BCR in patients with PCa and explored potential mechanisms regulated by the E2F family. This evidence concerns the gene E2F6 and posterior cortical atrophy.